Sign in

    David Rescot

    Senior Research Analyst at Robert W. Baird & Co. Incorporated

    David Rescott is a Senior Research Analyst at Robert W. Baird & Co. Incorporated, specializing in Medical Technology with coverage of major companies such as Haemonetics, Medtronic, LivaNova, Merit Medical Systems, Penumbra, Edwards Lifesciences, Boston Scientific, Intuitive Surgical, and SI-BONE. His performance track record includes frequent Outperform and Buy ratings, with recent calls such as a 41% projected upside on SI-BONE and 35% upside on Penumbra, and he was named a 2024 Rising Star of Equity Research by Business Insider. Rescott began his career at Canaccord Genuity in biomedical device research, later held analyst roles at Truist Securities, and joined Baird in 2023. He holds a BS in Business Administration and French from SUNY Geneseo, a Master of Science in Finance from Vanderbilt, and is FINRA registered with relevant securities licenses.

    David Rescot's questions to Nyxoah (NYXH) leadership

    David Rescot's questions to Nyxoah (NYXH) leadership • Q2 2025

    Question

    David Rescot of Baird sought clarification on the VAC and prior authorization processes, and asked about the timeline for the ACCESS study data and how the company can approach the CCC patient population before and after those results are available.

    Answer

    CFO John Landry and CEO Olivier Talman explained that the reimbursement process leverages the established AGNS CPT code, with approvals based on demonstrating GENEO's clinical efficacy. Talman reiterated that ACCESS data is expected in 12 months, with a potential label expansion by early 2027. He clarified that while CCC is not contraindicated, it is currently an off-label use in the U.S. and will not be actively promoted until the label is updated.

    Ask Fintool Equity Research AI